



HEPATITIS C AGENTS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Hepatitis C Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at: <https://www.pa.gov/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services>.

Office contact name/phone:		Prescriber name:	
LTC facility contact/phone:		State license #:	NPI:
Total # pages:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:
Requested drug #1:	Directions:	Qty:	<input type="checkbox"/> 8 weeks <input type="checkbox"/> 16 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> Other: _____
Requested drug #2:	Directions:	Qty:	<input type="checkbox"/> 8 weeks <input type="checkbox"/> 16 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> Other: _____

Is the beneficiary currently being treated with the requested drug(s)? Yes – Therapy start date: _____ No

SUBMIT DOCUMENTATION from the medical record for all items below.

For requests for NON-PREFERRED Hepatitis C Agents direct-acting antivirals (DAAs):

- Documentation that the beneficiary tried and failed or has a contraindication or intolerance to the preferred Hepatitis C Agents. (See the Preferred Drug List for the list of preferred Hepatitis C Agents at: <https://papdl.com/preferred-drug-list>.)
- Cirrhosis assessment documented by a recent noninvasive test and date of testing.
- Genotype if one of the following (check the appropriate box for the beneficiary):
 - The beneficiary is prescribed a non-pangenotypic regimen.
 - The beneficiary is hepatitis C sofosbuvir-based, sofosbuvir-velpatasvir-voxilaprevir, or sofosbuvir plus glecaprevir-pibrentasvir treatment-experienced.
 - The beneficiary has decompensated cirrhosis and is prescribed ledipasvir-sofosbuvir.
 - The beneficiary is treatment-naïve (with cirrhosis) and prescribed sofosbuvir-velpatasvir.
- RAS (resistance-associated substitutions) testing and date of testing if one of the following (check the appropriate box for the beneficiary):
 - The beneficiary is genotype 1a and prescribed elbasvir-grazoprevir.
 - The beneficiary is genotype 1a, treatment-experienced, and prescribed ledipasvir-sofosbuvir.
 - The beneficiary is genotype 3, treatment-naïve (with cirrhosis) or treatment-experienced (without cirrhosis) and prescribed 12 weeks of sofosbuvir-velpatasvir.

For requests for THERAPEUTIC DUPLICATION of Hepatitis C Agents direct-acting antivirals (DAAs):

For a beneficiary taking more than 1 Hepatitis C Agents DAA product concomitantly:

- The beneficiary has a medical reason for concomitant use of the requested products that is supported by peer-reviewed medical literature or national treatment guidelines.

For requests for ALL OTHER NON-PREFERRED Hepatitis C Agents (e.g., Pegasys): Diagnosis: _____

- The beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to first line therapies.

ATTESTATION from the prescriber for one of the items below.

Check the appropriate box for the beneficiary.

- The beneficiary is hepatitis C treatment naïve.
- The beneficiary has been treated for hepatitis C with the following treatment regimen: _____

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.